Intrexon Corporation (XON)

7.35
NASDAQ
Prev Close 7.20
Day Low/High 7.16 / 7.54
52 Wk Low/High 3.95 / 19.94
Exchange NASDAQ
Shares Outstanding 160.76B
Market Cap 1.16B
Div & Yield N.A. (N.A)

Latest News

Intrexon's Subsidiary Precigen To Present At The JMP Securities Life Sciences Conference

Intrexon's Subsidiary Precigen To Present At The JMP Securities Life Sciences Conference

GERMANTOWN, Md., June 13, 2019 /PRNewswire/ --  Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and its wholly-owned Intrexon Health subsidiary...

Oxitec Successfully Completes First Field Deployment Of 2nd Generation Friendly™ Aedes Aegypti Technology

Oxitec Successfully Completes First Field Deployment Of 2nd Generation Friendly™ Aedes Aegypti Technology

- First field trial achieved up to 96% suppression of target disease-transmitting mosquito populations in dense urban settings in Brazil

Intrexon Announces Advances In Non-Browning GreenVenus™ Romaine Lettuce

Intrexon Announces Advances In Non-Browning GreenVenus™ Romaine Lettuce

Non-Browning Romaine lettuce demonstrates improved shelf life, reducing food waste and is not subject to regulation as a product produced through genetic engineering by the USDA

Intrexon To Participate In 2019 BIO International Convention

Intrexon To Participate In 2019 BIO International Convention

GERMANTOWN, Md., May 28, 2019 /PRNewswire/ --   Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced the Company and its subsidiaries will...

No Backing Down: Cramer's 'Mad Money' Recap (Monday 5/20/19)

No Backing Down: Cramer's 'Mad Money' Recap (Monday 5/20/19)

Uncertainty over the trade war's effects on earnings make this market really hard on investors, says Jim Cramer.

Lululemon Athletica, Wayfair: 'Mad Money' Lightning Round

Lululemon Athletica, Wayfair: 'Mad Money' Lightning Round

Jim Cramer takes a look at Lululemon Athletica, Wayfair, Amazon, Intrexon, Iridium Communications, PayPal, Zscaler, Zynerba Pharmaceuticalsm and more.

Intrexon To Present At The Bank Of America Merrill Lynch 2019 Healthcare Conference

Intrexon To Present At The Bank Of America Merrill Lynch 2019 Healthcare Conference

GERMANTOWN, Md., May 13, 2019 /PRNewswire/ --  Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced Randal J.

Intrexon Reports First Quarter 2019 Financial Results

Intrexon Reports First Quarter 2019 Financial Results

-- Quarterly GAAP revenues of $23.3 million and net loss attributable to Intrexon of $60.7 million including non-cash charges of $17.8 million --

Intrexon To Release First Quarter 2019 Financial Results On May 9th

Intrexon To Release First Quarter 2019 Financial Results On May 9th

GERMANTOWN, Md., May 2, 2019 /PRNewswire/ --   Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced it will release first quarter 2019...

First Week Of June 21st Options Trading For Intrexon (XON)

First Week Of June 21st Options Trading For Intrexon (XON)

Investors in Intrexon Corp saw new options begin trading this week, for the June 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the XON options chain for the new June 21st contracts and identified one put and one call contract of particular interest.

Intrexon And Xogenex Present At American Society Of Gene And Cell Therapy Annual Meeting

Intrexon And Xogenex Present At American Society Of Gene And Cell Therapy Annual Meeting

GERMANTOWN, Md., April 29, 2019 /PRNewswire/ --  Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, and its majority owned Intrexon Health subsidiary...

Precigen Opens Gene And Cell Therapy Manufacturing Facility In Germantown, Maryland

Precigen Opens Gene And Cell Therapy Manufacturing Facility In Germantown, Maryland

-Nearly 5,000 square foot facility will manufacture early stage clinical trial material for gene therapy trials

Oxitec Signs New Multi-year Development Agreement To Apply 2nd Generation Technology To Control Soybean Looper

Oxitec Signs New Multi-year Development Agreement To Apply 2nd Generation Technology To Control Soybean Looper

Oxitec to develop a safe, self-limiting insect capable of reducing pest populations and reversing insect resistance to biotech traits and chemistries

Intrexon To Highlight Microbial Cannabinoid Production Platform At The Paradigm Capital Biosynthesis Conference

Intrexon To Highlight Microbial Cannabinoid Production Platform At The Paradigm Capital Biosynthesis Conference

GERMANTOWN, Md., April 10, 2019 /PRNewswire/ --   Intrexon Corporation (NASDAQ: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced Thomas D.

Oxitec Advances Self-Limiting Fall Armyworm Control Solution To Next Phase Of Development

Oxitec Advances Self-Limiting Fall Armyworm Control Solution To Next Phase Of Development

New collaboration agreement will advance scale-up and early field trials of Oxitec's self-limiting fall armyworm

Intrexon Intensifies Focus On Healthcare, Forms Two Units And Streamlines Management

Intrexon Intensifies Focus On Healthcare, Forms Two Units And Streamlines Management

- Move prompted by rapid progress at Intrexon's Precigen subsidiary -

First Week Of XON May 17th Options Trading

First Week Of XON May 17th Options Trading

Investors in Intrexon Corp saw new options begin trading this week, for the May 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the XON options chain for the new May 17th contracts and identified one put and one call contract of particular interest.

Textbook Rally: Cramer's 'Mad Money' Recap (Monday 3/11/19)

Textbook Rally: Cramer's 'Mad Money' Recap (Monday 3/11/19)

Jim Cramer explains why rallies on a sentiment switch are often among the best.

Akamai, Twitter, CenturyLink: 'Mad Money' Lightning Round

Akamai, Twitter, CenturyLink: 'Mad Money' Lightning Round

Jim Cramer weighs in on Akamai, Twitter, CenturyLink, Fluidigm, Ambarella, Intrexon, Del Taco Restaurants, Orange and more.

Intrexon And Surterra Wellness To Collaborate On Botticelli™ Next Generation Plant Propagation For Cannabis Cultivation

Intrexon And Surterra Wellness To Collaborate On Botticelli™ Next Generation Plant Propagation For Cannabis Cultivation

Companies to advance Intrexon's Botticelli™ platform to improve efficiency in cannabis plantlet production

Oversold Conditions For Intrexon (XON)

Oversold Conditions For Intrexon (XON)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Intrexon Reports 2018 Fourth Quarter And Year End Financial Results

Intrexon Reports 2018 Fourth Quarter And Year End Financial Results

- Quarterly GAAP revenues of $43.2 million and net loss attributable to Intrexon of $340.5 million including non-cash charges of $311.0 million -

Intrexon Partners With Next Green Wave To Advance Intrexon's Botticelli™ Next Generation Plant Propagation Platform Into Development For Cannabis

Intrexon Partners With Next Green Wave To Advance Intrexon's Botticelli™ Next Generation Plant Propagation Platform Into Development For Cannabis

Companies to apply Intrexon's proprietary Botticelli™ platform toward rapid and sustainable cannabis plantlet production

Intrexon Announces Presentations At Upcoming Investor Conferences

Intrexon Announces Presentations At Upcoming Investor Conferences

GERMANTOWN, Md., Jan.

TheStreet Quant Rating: D (Sell)